MiNK Therapeutics, Inc. Capital Expenditures
MiNK Therapeutics, Inc. (INKT) reported Capital Expenditures of $73.56 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-18
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $23.04K, a 61.46% decline year-over-year.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $37.02K.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $13.50K.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $73.56K, a 70.58% decline from fiscal 2022.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $250.05K, a 0.43% increase from fiscal 2021.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $248.98K, a 161.50% increase from fiscal 2020.
- MiNK Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2020 was $95.21K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $23.04K derived: sum of 2 quarters · filed 2025-03-18 | $60.06K derived: sum of 3 quarters · filed 2025-03-18 | $73.56K 10-K · filed 2025-03-18 |
| 2023-09-30 | $23.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $60.06K derived: sum of 2 quarters · filed 2024-11-14 | $73.56K 10-Q · filed 2024-11-14 | $201.40K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $37.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $50.52K 10-Q · filed 2024-08-13 | $178.36K derived: sum of 3 quarters · filed 2024-08-13 | $238.15K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $13.50K 10-Q · filed 2024-05-14 | $141.34K derived: sum of 2 quarters · filed 2024-05-14 | $201.13K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $127.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $187.63K derived: sum of 2 quarters · filed 2024-03-21 | $250.05K 10-K · filed 2024-03-21 | |
| 2022-09-30 | $59.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $122.21K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $62.41K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | -$277.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $111.54K derived: sum of 2 quarters · filed 2023-03-24 | $209.46K derived: sum of 3 quarters · filed 2023-03-24 | $248.98K 10-K · filed 2023-03-24 |
| 2021-09-30 | $111.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $209.74K derived: sum of 2 quarters · filed 2022-11-03 | $249.26K 10-Q · filed 2022-11-03 | $249.26K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $97.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $137.44K 10-Q · filed 2022-08-15 | $137.44K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $39.52K 10-Q · filed 2022-05-13 | $39.52K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $95.21K 10-K · filed 2022-03-18 | ||
| 2020-09-30 | $95.21K 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |